📰 globenewswire.com/news-release/2…
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
Up to $28.6 million in borrowing capacity through May 2029
“We intend to remain selective about financing decisions and disciplined in our use of capital,” said @DrRyanSaadi, O of Tevogen.
$TVGN #CapitalDiscipline #FinancialSustainability
Tevogen Complements Capital Access with Two-Year Extension to Loan Agreement
Up to $28.6 million in borrowing capacity through May 2029
“We intend to remain selective about financing decisions and disciplined in our use of capital,” said @DrRyanSaadi, O of Tevogen.
$TVGN #CapitalDiscipline #FinancialSustainability
0
6
7
119
We are a healthcare company focused on addressing unmet needs across biotechnology, technology, and healthcare services.
@TevogenBio: Biotechnology initiative focused on developing off-the-shelf cellular immunotherapies.
@TevogenAI: Leveraging artificial intelligence and advanced ce precision medicine.
@TevogenHS: A healthcare services initiative intended to support longer-term efforts to improve healthcare affordability, accessibility, and efficiency.
$TVGN
@TevogenBio: Biotechnology initiative focused on developing off-the-shelf cellular immunotherapies.
@TevogenAI: Leveraging artificial intelligence and advanced ce precision medicine.
@TevogenHS: A healthcare services initiative intended to support longer-term efforts to improve healthcare affordability, accessibility, and efficiency.
$TVGN
0
2
5
206
📰 globenewswire.com/news-release/2…
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
“I am pleased with Tevogen’s continued progress toward building an integrated healthcare enterprise,” said Dr. Manmohan Patel, MD, Tevogen’s lead investor. “The on represents an opportunity to expand the Company’s healthcare services capabilities and advance its mission of improving the affordability and accessibility of life-saving medicines. If consummated, this opportunity, together with other strategic acquisition initiatives, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue.”
$TVGN #strategic #acquisition
Tevogen Signs Letter of Intent to Evaluate Potential Acquisition of HRK Healthcare LLC
“I am pleased with Tevogen’s continued progress toward building an integrated healthcare enterprise,” said Dr. Manmohan Patel, MD, Tevogen’s lead investor. “The on represents an opportunity to expand the Company’s healthcare services capabilities and advance its mission of improving the affordability and accessibility of life-saving medicines. If consummated, this opportunity, together with other strategic acquisition initiatives, could potentially pave Tevogen’s path to realizing approximately $100 million in combined annual revenue.”
$TVGN #strategic #acquisition
0
2
3
402
📰 globenewswire.com/news-release/2…
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
🔹Both previously disclosed Nasdaq compliance matters are now closed
$TVGN @Nasdaq #Compliance
Tevogen Regains Compliance with Nasdaq Global Market Continued Listing Requirements
🔹Both previously disclosed Nasdaq compliance matters are now closed
$TVGN @Nasdaq #Compliance
0
5
8
562
📰 globenewswire.com/news-release/2…
Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: @TevogenBio, its biotechnology initiative; @TevogenAI, its artificial logy initiative; and @TevogenHS its healthcare services, its emerging healthcare services initiative.
Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.
“We are not simply building a biotechnology company. We are building a healthcare enterprise,” said @DrRyanSaadi, MD, MPH, Founder and Chief Executive Officer of Tevogen.
#TVGN
Tevogen is a healthcare enterprise focused on improving the affordability and accessibility of life-saving medicines. The Company brings together three complementary efforts: @TevogenBio, its biotechnology initiative; @TevogenAI, its artificial logy initiative; and @TevogenHS its healthcare services, its emerging healthcare services initiative.
Together, these efforts are designed to create a more integrated healthcare model in which science, technology, and operational efficiency work together to reduce the cost of medication and expand patient access.
“We are not simply building a biotechnology company. We are building a healthcare enterprise,” said @DrRyanSaadi, MD, MPH, Founder and Chief Executive Officer of Tevogen.
#TVGN
0
6
8
2,396
Tevogen Bio Announces 2026 Annual Meeting of Stockholders
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof.
$TVGN
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtually. Stockholders of record as of July 23, 2026 will be entitled to receive notice of and vote at the Annual Meeting or any adjournment thereof.
$TVGN
0
5
8
690
RT @Tevogen: Tevogen Bio Announces 2026 Annual Meeting of Stockholders
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtuall…
📰 globenewswire.com/news-release/2…
The Annual Meeting will be held virtuall…
0
6
0
25
#ICYMI
globenewswire.com/news-release/2…
🔹Lead investor confirmed his intention to maintain his current shareholdings.
🔹Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes proximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers.
🔹Company prioritizing long-term stock-based incentive program aligned with company milestones.
🔹Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.
🔹Company continues to evaluate acquisitions that could generate over $50 million in combined annual revenue.
🔹Company exploring avenues to better reflect value of assets.
$TVGN
globenewswire.com/news-release/2…
🔹Lead investor confirmed his intention to maintain his current shareholdings.
🔹Company does not anticipate using more than 1% of our authorized shares, including placement through the ATM, over the next 12 months or until the company becomes proximately only one-fifth of total shares outstanding are in the tradable float when accounting for Tevogen’s lead investor, directors and named executive officers.
🔹Company prioritizing long-term stock-based incentive program aligned with company milestones.
🔹Board of Directors continues to evaluate the potential declaration of a one-time special cash dividend to shareholders.
🔹Company continues to evaluate acquisitions that could generate over $50 million in combined annual revenue.
🔹Company exploring avenues to better reflect value of assets.
$TVGN
0
2
5
389
Tevogen retweeted
Shorting Innovation (and potentially U.S. National Security)
Shorting Innovation by Professor Nancy Kim: digitalcommons.lmu.edu/llr/vol57/iss3…
Founder $TVGN @TevogenBio @Tevogen @TevogenAI
Shorting Innovation by Professor Nancy Kim: digitalcommons.lmu.edu/llr/vol57/iss3…
Founder $TVGN @TevogenBio @Tevogen @TevogenAI
0
2
5
325
RT @DrRyanSaadi: The most powerful pharmacy in the world isn’t on a street corner. It’s already inside our veins. @TevogenBio - #Tcell
🌐 h…
🌐 h…
0
5
0
📰 globenewswire.com/news-release/2…
“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With ion in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.”
$TVGN #HealthcareEnterprise #StrategicAcquisitions #Revenue @DrRyanSaadi
“Tevogen’s evaluation of potential MSO and CRO acquisitions reflects a disciplined approach to building revenue-generating capabilities that may support long-term financial self-sufficiency,” said Kirti Desai, Chief Financial Officer at Tevogen. “With ion in potential combined annual revenue under evaluation, we believe these opportunities could represent an important step toward strengthening the Company’s financial foundation while remaining aligned with our mission to make healthcare more affordable and accessible.”
$TVGN #HealthcareEnterprise #StrategicAcquisitions #Revenue @DrRyanSaadi
0
4
8
350
“Bridging medical science and artificial intelligence to develop affordable, lifesaving therapies isn’t just innovation, it’s the future of medicine.” - Ryan Saadi, @CEO_TEVOGEN_BIO
$TVGN #JPMorganHealthcareConference #affordable #accessible #celltherapy #ICYMI
$TVGN #JPMorganHealthcareConference #affordable #accessible #celltherapy #ICYMI
0
3
7
350
At JPM43 Mittul Mehta, @Head_TevogenAI and @drhew
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Biopharma: Next Frontier of Medical Innovation
$TVGN $MSFT @DrRyanSaadi #Healthcare #ArtificialIntelligence #AI #Innovation #ICYMI
Chief Medical Officer & VP of Healthcare at
@Microsoft discussed AI in Biopharma: Next Frontier of Medical Innovation
$TVGN $MSFT @DrRyanSaadi #Healthcare #ArtificialIntelligence #AI #Innovation #ICYMI
0
4
6
560
Dr. Neal Flomenberg, Chief Scientific Officer, and Lori Grosso, Clinical Lead, discussed @TevogenBio's goal of making cytotoxic #Tcell #immunotherapy a #mainstream , outpatient treatment on @Nasdaq's Live from MarketSite.
$TVGN #affordable #accessible #celltherapy #oncology asdaq #ICYMI
$TVGN #affordable #accessible #celltherapy #oncology asdaq #ICYMI
0
2
4
483
RT @TevogenBio: 📰 tevogen.com/press-release/…
“Capital discipline and preserving the integrity of our capital structure are core priorities fo…
“Capital discipline and preserving the integrity of our capital structure are core priorities fo…
0
3
0
📰 tevogen.com/press-release/…
“Capital discipline and preserving the integrity of our capital structure are core priorities for us,” said @DrRyanSaadi, Founder and CEO of Tevogen. “Our strategic objective is to build a financially self-sufficient healthcare enterprise with the upport operations, advance growth initiatives, and create long-term value through revenue generation. The acquisition opportunities we are evaluating represent an initial phase of that strategy, and any related capital allocation decisions will continue to be guided by strategic fit, long-term value creation, and disciplined stewardship of Tevogen’s capital structure.”
$TVGN #StrategicAcquisitions #RevenueGeneration #HealthcareEnterprise
“Capital discipline and preserving the integrity of our capital structure are core priorities for us,” said @DrRyanSaadi, Founder and CEO of Tevogen. “Our strategic objective is to build a financially self-sufficient healthcare enterprise with the upport operations, advance growth initiatives, and create long-term value through revenue generation. The acquisition opportunities we are evaluating represent an initial phase of that strategy, and any related capital allocation decisions will continue to be guided by strategic fit, long-term value creation, and disciplined stewardship of Tevogen’s capital structure.”
$TVGN #StrategicAcquisitions #RevenueGeneration #HealthcareEnterprise
0
3
4
524